It's Finally Over for Aduhelm, the Sketchy Alzheimer's Drug Everyone Hated
The FDA approved Biogen's $56,000 anti-amyloid drug in 2021, against the advice of outside experts.
Stay updated with breaking news from Priya Singhal. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The FDA approved Biogen's $56,000 anti-amyloid drug in 2021, against the advice of outside experts.
Company to reprioritize resources allocated to ADUHELM® (aducanumab-avwa) to advance LEQEMBI® (lecanemab-irmb) and to develop new treatment modali...
Arizona State Retirement System cut its holdings in Biogen Inc. (NASDAQ:BIIB – Free Report) by 0.8% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 40,970 shares of the biotechnology company’s stock after selling 331 shares during the quarter. Arizona State Retirement […]
Wealthspire Advisors LLC acquired a new position in Biogen Inc. (NASDAQ:BIIB – Free Report) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 2,369 shares of the biotechnology company’s stock, valued at approximately $609,000. Other large investors have also recently modified their […]
Biogen (NASDAQ:BIIB – Get Free Report)‘s stock had its “outperform” rating restated by stock analysts at Oppenheimer in a note issued to investors on Tuesday, Benzinga reports. They currently have a $295.00 target price on the biotechnology company’s stock. Oppenheimer’s price objective points to a potential upside of 19.25% from the stock’s previous close. BIIB […]